Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action

DUBLIN and CAMBRIDGE, Mass., May 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, announced today the launch of the AboutYourGut.com website. On the heels of IBS Awareness Month, the hub's mission is to help educate sufferers impacted by irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) on these conditions, including providing information on condition management. The website is designed to resonate with people who are seeking an empathetic, optimistic and balanced point of view, offering expertly curated content as well as streamlined condition information, all within a clean, easy-to-navigate interface.

"Allergan and Ironwood Pharmaceuticals are pleased to provide this new educational resource for people who may be suffering from IBS-D, IBS-C or CIC, in an effort to encourage open, candid conversations with their healthcare professionals," said Aimee Lenar, Vice President, Gastroenterology and Psychiatry at Allergan. "AboutYourGut.com offers tools that can help patients identify their symptoms and help empower them to seek medical treatment."

AboutYourGut.com provides visitors the opportunity to learn more about the facts and figures associated with IBS-D, IBS-C and CIC, including prevalence and the impact these chronic conditions can have on patients. Website users should be able to better understand each condition based on causes, symptoms and potential treatment options available. They can take The Toilet Talk^SM Quiz that can help identify potential symptoms of IBS-D and learn more about their overall bowel health. They can also download symptom checklists for each condition to aid in their conversations with their healthcare providers.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI), or as a fixed-dose combination with allopurinol, for the treatment of hyperuricemia associated with gout. We are also advancing a pipeline of innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease, diabetic nephropathy, heart failure with preserved ejection fraction, achalasia and sickle cell disease. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

Forward-Looking Statement

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about AboutYourGut.com and its mission, prevalence and unmet need. Each forward‐looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to preclinical and clinical development, manufacturing and formulation development; the risk that future clinical studies need to be discontinued for any reason, including safety, tolerability, enrollment, manufacturing or economic reasons; the risk that findings from our completed nonclinical and clinical studies may not be replicated in later studies; efficacy, safety and tolerability; decisions by regulatory authorities; those risks related to competition and future business decisions made by us and our competitors or potential competitors; developments in the intellectual property landscape; and the risks listed under the heading "Risk Factors" and elsewhere in Ironwood's Annual Report on Form 10-K for the year ended December 31, 2017, Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and in the subsequent SEC filings of each company. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release, and Ironwood and Allergan undertake no obligation to update these forward-looking statements.

Allergan Contacts:
Daphne Karydas
(862) 261-8006

Amy Rose
(862) 261-7001

Tara Schuh
(862) 261-7637

Ironwood Contact:
Meredith Kaya
(617) 374-5082

SOURCE Allergan plc

Related Links

www.allergan.com